Fabry Exercise Intolerance Study (FEISTY)

Fabry Exercise Intolerance Study (FEISTY)

Patients and healthy controls will undergo cardiopulmonary exercises and testing of the muscles strength to gain additional understanding of exercise intolerance as Fabry disease (FD) manifestation. An additional needle muscle biopsy may be performed. Tissue analysis from this biopsy will include evaluation of the lipidomics profile and mitochondrial function. Results of the tests and any potential exercise intolerance will be compared against healthy, age-, sex- and BMI-matched volunteers. The hypothesis is that patients with FD will have reduced exercise capacity due to changes in skeletal and cardiac muscle energy metabolism.

Study Overview

• Status: Recruiting
• Conditions: Fabry Disease; Fabry Disease, Cardiac Variant
• Intervention / Treatment: Other: Intermittent cardiopulmonary exercise test; Other: Incremental cardiopulmonary exercise test

Detailed Description

Background: Fabry disease (FD) is an inherited, highly variable and slowly progressive X linked disorder, which predominantly affects vascular endothelium, the heart, kidneys and the brain. Exercise intolerance is a complaint expressed by the majority of patients, at all stages of the disease. The exact cause, extent and development over time of exercise intolerance in FD in insufficiently understood. This limits preventive measures and adequate treatment.

Hypothesis: 1) The development of energy metabolism in skeletal and cardiac muscle in FD is disturbed early on in disease development and this progresses as the disease worsens, resulting in reduced exercise capacity. 2) Intermittent CPX is an objective and sensitive tool to grade the level of exercise tolerance in FD patients and yields specific outcome parameters that can be used in future intervention studies.

Primary objectives: 1) To study the presence and extent of exercise intolerance in male, female FD patients with classical FD and men with non-classical FD, in different stages of the disease. 2) To determine the aetiology of exercise intolerance in FD. Secondary objectives: 1) To determine whether the exercise test protocol used in this study can be used as a clinical outcome measure in future intervention studies. 2) To investigate difference in the time-relation between V'O2 and circulatory, ventilatory and metabolic variables during intermittent exercise between FD patients groups (potentially providing an indication of the source of possibly slowed V'O2 kinetics).

Methods: This study will consist of two screening visits, one testing procedure visit, and an optional second visit for all subjects enrolled in the study. During the first testing visit two cardiopulmonary exercise (CPX) test will be performed. During the CPX tests gas exchange, ventilation, blood pressure and cardiac output will be measured and exhaustion level monitored. Before and after the tests a blood sample will be taken. The upper leg muscle strength and the leg muscle size will be assessed. In order to detect alterations in skeletal muscle energy metabolism, a needle biopsy of the upper leg muscle will be taken during the second optional study visit. In the biopsy specimen, lipidomics profile, electronic microscopic characteristics of muscle tissue and mitochondrial function will be assessed.

• Study Type: Observational
• Enrollment (Estimated): 30

Contacts and Locations

• Study Contact: Name: Bram Veldman, MD; Phone Number: 0031205666791; Email: b.c.f.veldman@amsterdamumc.nl

Study Locations

• Netherlands
  • Amsterdam, Netherlands, 1105AZ
    • Recruiting
    • Amsterdam UMC, location AMC
    • Contact: Bram Veldman

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Population of FD patients, either with a classical or a non-classical phenotype.

Population of healthy controls.

Description

Inclusion Criteria:

• FD patients: Men and women with a definite known diagnosis of FD.
• Healthy controls: Healthy control subjects (men and women) with an age of 18 years of older.

Exclusion Criteria:

FD patients:

• Pregnancy
• Recent acute myocardial infarct (<6 months)
• Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third-degree AV block) causing hemodynamic compromise
• Implantable pacemaker or other cardiac device with complete ventricular pacing
• Uncontrolled heart failure with hemodynamic compromise
• Uncontrolled hypertension (Systolic Blood Pressure >150 mmHg and Diastolic Blood Pressure >100 mmHg on repeated measurements)
• Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate <30 ml/min/1,73m2) likely to significantly impact on exercise performance
• In some cases: use of anticoagulants or anti platelet therapy (see study procedure)

Healthy controls:

• All abovementioned exclusion criteria for FD patients
• History of smoking
• History of active drug use which can affect exercise intolerance
• History of asthma, chronic obstructive pulmonary disease, heart failure, heart surgery, heart rhythm disorders or congenital heart diseases
• Use of chronic medication likely to affect exercise tolerance
• Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
• >6 alcohol units per day or >14 alcohol units per week

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Men with classical Fabry disease	Other: Intermittent cardiopulmonary exercise test; Exercise test with step-change from rest to a relatively low constant workload.; Other: Incremental cardiopulmonary exercise test; Exercise test with incremental workload until maximal workload.
Women with classical Fabry disease	Other: Intermittent cardiopulmonary exercise test; Exercise test with step-change from rest to a relatively low constant workload.; Other: Incremental cardiopulmonary exercise test; Exercise test with incremental workload until maximal workload.
Men with non-classical Fabry disease	Other: Intermittent cardiopulmonary exercise test; Exercise test with step-change from rest to a relatively low constant workload.; Other: Incremental cardiopulmonary exercise test; Exercise test with incremental workload until maximal workload.
Healthy controls; Age-, Sex-, BMI-matched controls	Other: Intermittent cardiopulmonary exercise test; Exercise test with step-change from rest to a relatively low constant workload.; Other: Incremental cardiopulmonary exercise test; Exercise test with incremental workload until maximal workload.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in V'O2 max kinetics (ml/kg/min)		At rest (baseline) and after maximum CPX test (30 min)
Tiffeneau-index (FEV1/IVC ratio)	Pulmonary involvement	At rest (baseline)
Anaerobic threshold (ml/kg/min)	Pulmonary involvement/Cardiac dysfunction/Skeletal muscle alterations	During maximum exercise (max 30 min).
Ventilation reserve (L)	Pulmonary involvement/Skeletal muscle alterations	During maximum exercise (max 30 min).
CO2 ventilation equivalent (L/L)	Pulmonary involvement/Cardiac dysfunction	During maximum exercise (max 30 min).
O2 saturation (%)	Pulmonary involvement/Cardiac dysfunction	During maximum exercise (max 30 min).
Cardiac Output (L/min)	Cardiac dysfunction	During maximum exercise (max 30 min).
Heart rate reserve (per minute)	Cardiac dysfunction:	During maximum exercise (max 30 min).
Muscle size on echography (cm)	Skeletal muscle alterations	Baseline
Muscle strength via resistance test (kg)	Skeletal muscle alterations	Biopsy at baseline
Lipidomics profile of muscle tissue	Skeletal muscle alterations	Biopsy at baseline
Electronic microscopic characteristics of muscle tissue	Skeletal muscle alterations	Biopsy at baseline
Mitochondrial function of muscle tissue	Skeletal muscle alterations	Biopsy at baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
Correlation between V'O2 kinetics during intermittent exercise and V'O2 max on the incremental maximum CPX (Pearson correlation coefficient).	Day 1
Correlation between V'O2 kinetics during intermittent exercise and activity score on the SQUASH Questionnaire (Pearson correlation coefficient).	Day 1
Correlation between V'O2 kinetics during intermittent exercise and functional and morphological cardiac parameters on cardiac imaging (Magnetic resonance or echocardiography) (Pearson correlation coefficient).	Day 1

Other Outcome Measures

Outcome Measure	Time Frame
Body height (cm)	Baseline
Body weight (kg)	Baseline
NT-proBNP (ng/L)	Baseline
Troponin (μg/L)	Baseline
Lactate (mmol/L)	Baseline and after maximum exercise
Haemoglobin (mmol/L)	Baseline

Collaborators and Investigators

• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2021
• Primary Completion (Estimated): January 2, 2024
• Study Completion (Estimated): January 2, 2024

Study Registration Dates

• First Submitted: May 17, 2022
• First Submitted That Met QC Criteria: June 9, 2022
• First Posted (Actual): June 10, 2022

Study Record Updates

• Last Update Posted (Actual): August 24, 2023
• Last Update Submitted That Met QC Criteria: August 23, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Metabolic Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Lipid Metabolism Disorders; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Cerebral Small Vessel Diseases; Lipidoses; Lipid Metabolism, Inborn Errors; Fabry Disease
• Other Study ID Numbers: NL73534.018.21

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No